Compare REAL & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REAL | FTRE |
|---|---|---|
| Founded | 2011 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2019 | 2023 |
| Metric | REAL | FTRE |
|---|---|---|
| Price | $9.85 | $16.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $17.00 | $14.06 |
| AVG Volume (30 Days) | ★ 2.8M | 1.1M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.55 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $692,845,000.00 | ★ $2,723,400,000.00 |
| Revenue This Year | $14.30 | N/A |
| Revenue Next Year | $10.15 | $3.09 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.38 | 1.00 |
| 52 Week Low | $4.71 | $4.46 |
| 52 Week High | $17.39 | $18.67 |
| Indicator | REAL | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 49.61 | 65.72 |
| Support Level | $9.61 | $15.66 |
| Resistance Level | $9.94 | $18.08 |
| Average True Range (ATR) | 0.51 | 1.07 |
| MACD | 0.06 | 0.09 |
| Stochastic Oscillator | 82.04 | 84.94 |
The RealReal Inc is an online marketplace for authenticated, resale luxury goods, providing an end-to-end service that unlocks supply and creates a trusted, curated marketplace for buyers globally. Since its inception, the company has cultivated a loyal and engaged consignor and buyer base through continuous investment in its technology platform, logistics infrastructure, brand and people. It offers a wide selection of authenticated, mainly pre-owned luxury goods bearing the brands of thousands of luxury and premium designers, including Cartier, Chanel, Christian Dior, Gucci, Hermes, Louis Vuitton and Rolex. The company offers products across women's fashion, men's fashion, jewelry, and watches, promoting the recirculation of luxury goods and contributing to a more sustainable world.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.